Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9203MR)

This product GTTS-WQ9203MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9203MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3496MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ16008MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ1426MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ14527MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ2469MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ9607MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ14189MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ3119MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW